stockrow
Saturday 7 November 2026
Export RIGL’s income statement to Excel — free account
Rigel Pharmaceuticals, Inc.
RIGL Healthcare Biotechnology
Rigel Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $294.3 million, up 64.1% from fiscal 2024.
- Revenue
- +16.5%
- EPS
- −54.8%
- Free cash flow
- +43.9%
- Total debt
- −66.6%
Quarter to September 2026, against a year earlier
39.59
6.12
−13.39%
Follow RIGL
Alert me
Rigel Pharmaceuticals, Inc. (RIGL) P/E ratio
As of 6 November 2026, Rigel Pharmaceuticals, Inc. (RIGL) trades at a P/E ratio of 2.4×. Over the past ten years it has ranged from 0.0× (September 2024) to 143× (November 2024); the current reading is higher than 87% of that period. That is below the Biotechnology industry median of 10.6× and below the Healthcare sector median of 24.5×.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 2.1× | (87.92%) |
| FY2024 | 17.5× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Sep 2026 | 2.9× | 29.31% |
| Jun 2026 | 2.2× | 64.32% |
| Mar 2026 | 1.3× | (36.33%) |
| Dec 2025 | 2.1× | (52.72%) |
| 40 more quarters | Free account |
Against its own ten years
Low 0.0×
High 143×
Ten-year median
0.0×
Current reading's percentile
87
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| GLUE Monte Rosa Therapeutics, Inc. compare | n/m |
| ANRO Alto Neuroscience, Inc. compare | n/m |
| ORIC Oric Pharmaceuticals, Inc. compare | n/m |
| AKTS Aktis Oncology, Inc. compare | n/m |
| IVA Inventiva S.A. Sponsored ADR compare | n/m |
| SNDX Syndax Pharmaceuticals, Inc. compare | n/m |
| RIGL Rigel Pharmaceuticals, Inc. | 2.4× |
| PHAR Pharming Group N.V. Sponsored ADR compare | 34.2× |
| LTGO Latigo Biotherapeutics Inc compare | — |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)